Business Profile

Description: We are pioneering the development of synthetic biomarkers – biological sensors developed using breakthroughs in science, engineering, medicine and artificial intelligence – that are bioengineered to be perfectly tunable to any disease, absolutely specific, and offer earlier measures of response to disease and treatment. Our synthetic biomarkers are administered to patients and tailor-made to query the activity of key biological targets such as proteases – a class of enzymes that drive critical disease pathways. Synthetic biomarkers exploit the human body’s own proteases and in vivo trafficking to create perfectly refined and trackable markers of disease which are accurate, sensitive, specific and detectable in a simple noninvasive urine test. It’s the new frontier of liquid biopsy. Our lead indication is in NASH, and our second indication is in Oncology. Our development pipeline is broad, and we have preclinical validation in over 10 diseases.